Navigation Links
Parkinson's Disease Foundation Awards $300,000 in Bridge Funding for Innovative Research Projects
Date:2/19/2009

NEW YORK, Feb. 19 /PRNewswire-USNewswire/ -- The Parkinson's Disease Foundation (PDF) has awarded $300,000 in emergency bridge funding to four leading Parkinson's disease scientists. The grants will sustain promising investigations that were recently put into jeopardy by the sudden collapse of their primary private funder, The Picower Foundation.

The Picower Foundation, whose endowment was managed by Bernard Madoff, was forced to cease all grantmaking activities as of the end of 2008.

The awards will support four innovative research projects that were affected by this turn of events, with one-time grants of $75,000 each. The lead scientists on these projects, known in the field for their outstanding work in Parkinson's disease, include J. Timothy Greenamyre, M.D., Ph.D., of the University of Pittsburgh School of Medicine, Virginia M.-Y. Lee, Ph.D., of the University of Pennsylvania School of Medicine, David Sulzer, Ph.D., of Columbia University Medical Center and D. James Surmeier, Ph.D., of Northwestern University Feinberg School of Medicine.

Each project is pursuing a novel avenue of research that may shed light on new ways of treating Parkinson's. Dr. Greenamyre, for example, will test several classes of medications already approved by the FDA for diseases other than Parkinson's to observe whether they are effective in improving gastrointestinal motility in Parkinson's. Despite the frequency and debilitating nature of this nonmotor symptom for people living with Parkinson's, there are no drugs designed specifically to address it.

Dr. Lee, along with John Q. Trojanowski, M.D., Ph.D., is focused on drug discovery, targeting the misfolding, or clumping, of a protein called alpha-synuclein. This clumping is believed to contribute to the cell death that leads to Parkinson's. Their team will test a variety of known compounds to determine if any are effective in preventing the protein clumping and will examine the most promising candidates for their potential to not only treat Parkinson's, but also to theoretically slow its progression.

Dr. Sulzer will investigate the role that inflammation, caused by an immune response, plays in causing the death of neurons in Parkinson's. Scientists already know that inflammation occurs in areas of the brain affected by Parkinson's disease and suspect that it may trigger cell death. By taking a fresh approach to understanding how inflammation is initiated, Dr. Sulzer's work may yield a better understanding of how Parkinson's develops, pointing toward new ways of treating the disease.

Dr. Surmeier will explore the idea that areas of the brain affected by Parkinson's, some of which have not been traditionally studied, may share a common mechanism that contributes to the death of neurons. He hypothesizes that this mechanism may involve excess levels of calcium inside cells. If Dr. Surmeier's high risk approach is on target, he says it may be very easy to identify a treatment that could concurrently ease the motor and nonmotor symptoms of Parkinson's, something that is not feasible with current therapies. One possibility includes isradipine, a medication already on the market for high blood pressure.

Dr. Lee, of the University of Pennsylvania School of Medicine, noted, "With PDF's help, we will be able to continue our research, the ultimate goal of which is to expand the 'pipeline' of promising compounds for novel Parkinson's therapies."

PDF Executive Director, Robin Anthony Elliott said of the grants, "Our board of directors and my colleagues at PDF were deeply affected by how the loss of one family foundation and its millions of dollars of support can have such a direct and catastrophic effect upon Parkinson's disease research. We are not only proud to support some of the talented scientists left in the wake of this event, but also believe that we owe this type of commitment to the nearly one million people in the US living with Parkinson's - people who cannot afford, even in a time of economic uncertainty, for promising research to be put on hold."

These grants are part of PDF's four-pronged approach to funding Parkinson science. PDF's research initiatives include a Center Grants Program, which funds research at three leading universities; the International Research Grants Program, which provides seed grants to promising scientists studying the science of Parkinson's disease; career development and fellowship programs that support continued interest in the field of Parkinson's; and collaborative endeavors with other organizations that fund Parkinson's disease research. In fiscal year 2009, PDF will contribute $5.4 million to support Parkinson's disease research.

About Parkinson's Disease

Parkinson's disease is a progressive neurological disorder that affects nearly one million people in the US. Although promising research is being conducted, there is currently no cure for Parkinson's.

About the Parkinson's Disease Foundation (PDF)

The Parkinson's Disease Foundation(R) (PDF(R)) is a leading national presence in Parkinson's disease research, education and public advocacy. We are working for the nearly one million people in the US living with Parkinson's by funding promising scientific research and supporting people with Parkinson's, their families and caregivers through education programs and support services. Since its founding in 1957, PDF has funded over $75 million worth of scientific research in Parkinson's disease, supporting the work of leading scientists throughout the world.


'/>"/>
SOURCE Parkinson's Disease Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Risk of Stroke, Heart Disease in Women Lowered by Mediterranean Diet
2. Update of Long-Term Data on Brain Cancer Patients Receiving DCVax(R)-Brain Continues to Show Striking Improvements in Delay of Disease and Survival
3. Groundbreaking Paper Publishes Long Term Results of a Successful Phase I Clinical Trial Using Autologous Neural Stem Cells to Treat Parkinsons Disease
4. Evidence Lacking in Multivitamin Study of Womens Risk of Cancer, Heart Disease or Death, Says Natural Products Association
5. February 2009 Mayo Clinic Womens HealthSource Highlights Diabetes and Heart Disease, Going Vegetarian and Tinnitus
6. Medgenics Announces Positive Data From Phase I/II Clinical Trial of EPODURE Treatment of Anemia in Chronic Kidney Disease
7. Merck Seronos Safinamide Significantly Improved Motor Function in Patients With Advanced Parkinsons Disease in a Phase III Pivotal Trial
8. Mayo Clinic Study Finds Younger Men With Erectile Dysfunction at Double Risk of Heart Disease
9. New Research Suggests Platelet Stickiness May be the Single Most Important Risk Factor in Patients Treated with Coronary Stents - Findings May be Applicable to Anyone with Vascular Disease
10. Cardiac Disease in Women Remains Untreated for Decades
11. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... , March 30, 2017 The topical ... $92.40 billion in 2016, growing at a CAGR of 6.4% ... is will be major end-user in market. While ... forecast period. ... Browse 87 tables and 41 figures, 10 Company profiles ...
(Date:3/30/2017)... -- Research and Markets has announced the addition ... Forecast, By Type (Hemodialysis, Peritoneal Dialysis), By Product (Device, Consumables, ... To 2025" report to their offering. ... The global hemodialysis ... billion by 2025. Home-based dialysis treatment ...
(Date:3/29/2017)... Research and Markets has announced the addition of the ... ... energy-based aesthetic devices market to grow at a CAGR of 8.12% ... Aesthetic Devices Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
Breaking Medicine Technology:
(Date:3/29/2017)... Massachusetts (PRWEB) , ... March 30, 2017 , ... Youth ... had great success and feedback from high school and college students who have participated ... being held July 7-23 and YFI is now accepting applications for enrollment. Visit ...
(Date:3/29/2017)... ... March 30, 2017 , ... Sports Brand EXOUS Bodygear ... which retails normally at $29.97; for the remaining days of March, the price will ... reduced to a special price of just $10 (regular retail price $19.97). , The ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... ... three Hours at a Walgreens store in Mississippi. AngioGenesis Labs, makers of HeartBoost, ... Stores in two southeastern states. Ingredients in HeartBoost, an over the counter heart ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... provides insight into the challenges employers face in trying to balance both short-term ... employee benefits programs? Adding to the growing complexity, companies are finding that ...
(Date:3/29/2017)... ... March 29, 2017 , ... Dr. Angela Cotey, a noted general ... accepting new pediatric patients, with or without a referral. Dr. Cotey knows that ... orthodontic outcome and experience. When patients receive early treatment, they may achieve straight teeth ...
Breaking Medicine News(10 mins):